Efficacy and Safety of Rejuviel V in the Correction of Midface Volume Deficit
NCT: NCT07162610 · COMPLETED
Brief Summary
The purpose is to evaluate the efficacy and confirm the safety of Rejeunesse Contour® with Lidocaine compared to Juvederm® Voluma® with Lidocaine for the temporary improvement of mid-face volume (including the cheekbone area, the anterior-medial cheek, and the area below the cheekbone). The investigational medical device will be administered a total of once during the entire clinical trial period (or up to twice if additional treatment is required). After the administration, photographs of the application site and evaluations using the Mid-Face Volume Deficit Scale (MFVDS) will be conducted at 4 weeks, 12 weeks, 24 weeks, and 48 weeks. Satisfaction with mid-face volume improvement will be assessed using the Global Aesthetic Improvement Scale (GAIS). Additionally, changes in concomitant medications/treatments and adverse events will be reviewed in comparison to the previous visit.
Frequently Asked Questions
What is Efficacy and Safety of Rejuviel V in the Correction of Midface Volume Deficit?
Efficacy and Safety of Rejuviel V in the Correction of Midface Volume Deficit is a clinical trial registered under NCT07162610. Current status: COMPLETED.
What is the status of NCT07162610?
The current status of NCT07162610 (Efficacy and Safety of Rejuviel V in the Correction of Midface Volume Deficit) is: COMPLETED.
When did Efficacy and Safety of Rejuviel V in the Correction of Midface Volume Deficit start?
Efficacy and Safety of Rejuviel V in the Correction of Midface Volume Deficit started on 2024-04-07.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.